alisertib
Showing 1 - 25 of 36
Small Cell Lung Cancer Trial in Cleveland (Alisertib)
Not yet recruiting
- Small Cell Lung Cancer
- Alisertib
-
Cleveland, OhioCleveland Clinic
Oct 18, 2023
Lung Cancer, Mesothelioma Trial in Houston (Alisertib)
Completed
- Lung Cancer
- Mesothelioma
- Alisertib
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Sep 23, 2022
Head and Neck Squamous Cell Carcinoma, Malignant Solid Tumor Trial in Houston (Alisertib, Pembrolizumab)
Recruiting
- Head and Neck Squamous Cell Carcinoma
- Malignant Solid Neoplasm
- Alisertib
- Pembrolizumab
-
Houston, TexasM D Anderson Cancer Center
Dec 31, 2022
Lung Cancer Metastatic, EGFR Gene Mutation Trial in San Francisco (Osimertinib, Alisertib)
Recruiting
- Lung Cancer Metastatic
- EGFR Gene Mutation
- Osimertinib
- Alisertib
-
San Francisco, CaliforniaUniversity of California, San Francisco
Aug 10, 2022
Recurrent Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8 Trial in Houston
Active, not recruiting
- Recurrent Lung Non-Small Cell Carcinoma
- +4 more
- Alisertib
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Jul 31, 2022
Metastatic Breast Cancer, Solid Tumors Trial in Aurora (Alisertib, MLN0128)
Completed
- Metastatic Breast Cancer
- Solid Tumors
- Alisertib
- MLN0128
-
Aurora, ColoradoUniversity of Colorado Cancer Center
May 17, 2022
Malignant Rhabdoid Tumor, Atypical Teratoid Rhabdoid Tumor Trial in United States (drug, procedure, radiation)
Recruiting
- Malignant Rhabdoid Tumor
- Atypical Teratoid Rhabdoid Tumor
- alisertib
- +9 more
-
Los Angeles, California
- +10 more
Aug 1, 2022
Acute Megakaryoblastic Leukemia, Myelofibrosis, Primary Myelofibrosis Trial in Miami, Chicago, Rochester (Alisertib, Laboratory
Active, not recruiting
- Acute Megakaryoblastic Leukemia
- +2 more
- Alisertib
- +2 more
-
Miami, Florida
- +2 more
May 4, 2021
Acute Myeloid Leukemia Trial in Boston (Alisertib, Cytarabine, Idarubicin)
Completed
- Acute Myeloid Leukemia
- Alisertib
- +3 more
-
Boston, Massachusetts
- +1 more
Apr 23, 2020
Advanced Nonhematologic Malignancies Trial in Worldwide (MLN2480, MLN0128, Alisertib)
Completed
- Advanced Nonhematologic Malignancies
- MLN2480
- +5 more
-
Boston, Massachusetts
- +13 more
Feb 11, 2020
Advanced Solid Tumors, Relapsed/Refractory Lymphoma Trial in United States (Alisertib, Itraconazole)
Completed
- Advanced Solid Tumors
- Relapsed/Refractory Lymphoma
- Alisertib
- Itraconazole
-
Saint Louis, Missouri
- +3 more
Aug 16, 2019
Advanced Solid Tumors, Ovarian Cancer, Small Cell Lung Cancer Trial in Chiba, Shizuoka, Seoul (Alisertib, Paclitaxel)
Malignant Tumor of Breast, CNS Malignancy, Malignant Tumor of Gastrointestinal Tract Trial in Chicago (Alisertib, Pazopanib)
Completed
- Malignant Neoplasm of Breast
- +6 more
- Alisertib
- Pazopanib
-
Chicago, IllinoisUniversity of Illinois Cancer Center
Jul 18, 2019
Bladder Cancer, Transitional Cell Carcinoma Trial in Milano (Alisertib, Paclitaxel, Placebo)
Completed
- Bladder Cancer
- Transitional Cell Carcinoma
- Alisertib
- +2 more
-
Milano, Mi, ItalyFondazione IRCCS Istituto Nazionale dei Tumori
Apr 9, 2019
Solid Tumors, Lymphoma Trial in United States (Alisertib, Esomeprazole, Rifampin)
Completed
- Solid Tumors
- Lymphoma
- Alisertib
- +2 more
-
Sarasota, Florida
- +6 more
Dec 18, 2018
Advanced Solid Tumors, Lymphomas Trial in Tiong Bahru (Alisertib)
Completed
- Advanced Solid Tumors
- Lymphomas
- Alisertib
-
Tiong Bahru, SingaporeNational Cancer Centre
Nov 29, 2018
Advanced and Metastatic Gastric or Gastroesophageal Adenocarcinoma Trial in Spain, United States (MLN1117, TAK-659, Alisertib)
Terminated
- Advanced and Metastatic Gastric or Gastroesophageal Adenocarcinoma
- MLN1117
- +4 more
-
Lake Success, New York
- +5 more
Aug 19, 2019
Advanced Solid Tumors, Adenocarcinoma of the Prostate Trial in United States (Alisertib, Docetaxel)
Completed
- Advanced Solid Tumors
- Adenocarcinoma of the Prostate
- Alisertib
- Docetaxel
-
Indianapolis, Indiana
- +3 more
Oct 4, 2018
Advanced Solid Tumors, Lymphoma Trial in Tacoma ([^14C]-alisertib, alisertib)
Completed
- Advanced Solid Tumors
- Lymphoma
- [^14C]-alisertib
- alisertib
-
Tacoma, WashingtonComprehensive Clinical Development
Feb 20, 2018
Advanced Solid Tumors Trial in Santa Monica (Alisertib)
Completed
- Advanced Solid Tumors
- Alisertib
-
Santa Monica, CaliforniaPremiere Oncology, A Medical Corporation
Mar 8, 2019
Advanced Solid Tumors, Relapsed/Refractory Lymphoma Trial in United States (Alisertib)
Completed
- Advanced Solid Tumors
- Relapsed/Refractory Lymphoma
- Alisertib
-
Miami, Florida
- +6 more
Apr 9, 2018
Advanced Malignancies Trial in Nashville (Alisertib)
Completed
- Advanced Malignancies
- Alisertib
-
Nashville, TennesseeSarah Cannon Research Institute (SCRI)
Nov 29, 2018
Estrogen Receptor Positive, Progesterone Receptor Positive, Recurrent Breast Carcinoma Trial in Rochester (Alisertib,
Completed
- Estrogen Receptor Positive
- +5 more
- Alisertib
- +2 more
-
Rochester, MinnesotaMayo Clinic
Oct 2, 2018